Rocket Lab Stock Has Collapsed 57% From Highs. Here's Why I'm Not Buying (Yet).

Rocket Lab shares are down 57% from recent highs, despite a bullish outlook around its $2.3B backlog, Iridium acquisition, and the Neutron rocket path to scale. The company plans to acquire Iridium for $8B in a half-stock/half-cash deal and expects an FCFS cash-flow boost from Iridium ($288M positive FCF over the last 12 months), but it remains unprofitable with -$371M free cash flow over the last 12 months. Valuation is a key constraint: the stock trades at a 48x trailing P/S vs the S&P 500 at 3.8x, leading the author to suggest waiting for a much lower price (possibly ~50% below today).

Analysis

This is still a narrative stock, not a self-funding compounder. Near term, the market is paying for a future platform that depends on flawless execution across launch cadence, integration, and capital allocation; any slippage on Neutron or the acquisition timetable should compress the multiple fast because the equity story is doing more work than the P&L. The incremental free cash flow from the target helps optics, but it does not eliminate the core issue: the combined company still needs to prove it can convert backlog into returns without persistent dilution.

Competitive dynamics matter more than the headline transaction. A vertically integrated launch-plus-comms stack can strengthen negotiating leverage with government buyers, but it also creates vendor-neutrality concerns that could push large customers toward primes like LMT/NOC or toward diversified connectivity alternatives such as ASTS/GSAT. Over 1-3 months, the real catalyst is not backlog; it is whether management can show schedule discipline and a cleaner path to positive operating leverage. Over 6-18 months, the thesis rises or falls on whether Neutron becomes a repeatable product rather than a one-off event.

The consensus is probably missing how fragile the scarcity premium is. The stock can stay expensive for a long time if the market keeps treating it as the nearest public proxy to SpaceX, but that premium is vulnerable to one missed milestone or a disappointing integration update. Conversely, if the first Neutron launch lands and the company keeps raising guidance without fresh equity, the de-rating case is wrong; until then, this looks like a high-beta watchlist name rather than a clean buy.

Key Decisions for Investors

• Do not chase RKLB here; wait for a 20-30% pullback or a post-catalyst reset before initiating a long, because current valuation already discounts a lot of execution success.
• Tactically short RKLB on strength via shares or 3-6 month put spreads; use successful Neutron first-flight confirmation or raised 2026-2027 operating guidance as the stop/falsifier.
• If merger terms remain unchanged, consider a relative-value expression of skepticism with long IRDM / short RKLB only as a spread trade around the close window; the edge is in preferring current FCF over promised future scale.
• Keep a watchlist on LMT, NOC, ASTS, and GSAT for second-order beneficiary flows if large buyers prefer vendor-neutral alternatives to a vertically integrated RKLB stack.